Welcome to our dedicated page for Compass Pathways news (Ticker: CMPS), a resource for investors and traders seeking the latest updates and insights on Compass Pathways stock.
COMPASS Pathways plc reports biotechnology developments centered on COMP360, its proprietary synthetic psilocybin treatment candidate for serious mental health conditions, with treatment-resistant depression as the primary disclosed focus. News commonly covers clinical data, FDA and UK regulatory designations, NDA submission and review activity, and the company's work on delivery models for psychedelic treatment in clinical settings.
Recurring updates also include financial results and business highlights, investor conference participation, collaborations with psychiatry and care-delivery organizations, healthcare provider training initiatives, and equity compensation actions under Nasdaq rules. As an ADR-listed issuer, CMPS news can reflect parent-company operating updates and American Depositary Share-related corporate actions.
COMPASS Pathways (Nasdaq: CMPS) announced its addition to the Nasdaq Biotechnology Index, effective December 20, 2021. This index tracks biotech and pharmaceutical securities, making it significant for institutional investors. CEO George Goldsmith expressed pride in this achievement, which aims to enhance visibility as the company advances its COMP360 psilocybin therapy for mental health. This therapy has received FDA Breakthrough Therapy designation for treatment-resistant depression and has shown statistically significant clinical trial results.
COMPASS Pathways (Nasdaq: CMPS) has appointed Matthew Owens as its new General Counsel and Chief Legal Officer, effective February 1, 2022. Owens joins from Novartis, where he was the Global Head of Legal, Digital. Concurrently, Lars Wilde, co-founder and Chief Business Officer, will transition to a senior advisory role from January 1, 2022. Under Wilde's leadership, COMPASS raised over $429 million and advanced its psilocybin therapy for mental health, which has received Breakthrough Therapy designation from the FDA.
COMPASS Pathways (Nasdaq: CMPS) announced positive results from its study of COMP360 psilocybin therapy in patients concurrently taking SSRIs. In this phase IIb trial, 19 patients treated with a 25mg dose had comparable outcomes to those who discontinued SSRIs before treatment. 42.1% of participants responded after three weeks, with an average MADRS score reduction of 14.9. Notably, no serious adverse events emerged. COMPASS is now preparing to meet with the FDA to finalize its phase III program planned to start in Q3 2022.
COMPASS Pathways plc (Nasdaq: CMPS) announced the appointment of Michael Falvey as Chief Financial Officer, effective January 1, 2022. He replaces Piers Morgan, who departs at year-end. Falvey has a robust background in finance, having previously led financial strategies at Karyopharm Therapeutics and other growth companies. His expertise will be vital as COMPASS advances its psilocybin therapy for treatment-resistant depression, especially following recent positive Phase IIb clinical trial results. The company has raised over $425 million and aims to transform mental health care.
COMPASS Pathways (Nasdaq: CMPS) announced positive results from its phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression (TRD). Additional analyses validated prior findings, showing significant improvements in depression symptoms and overall patient functioning with a 25mg dose compared to 1mg. Outcomes measured at three weeks revealed a -6.6 difference on the MADRS scale (p0.001). Safety analysis indicated that COMP360 was generally well-tolerated, with most adverse events resolving quickly. The company anticipates starting a pivotal phase III trial in .
COMPASS Pathways plc (Nasdaq: CMPS) announced the granting of its 10th patent, specifically US Patent No 11,180,517, which focuses on treatment-resistant depression (TRD) using crystalline psilocybin. With five patents in the US, the latest patent reinforces the company’s commitment to advancing mental health therapies. COMPASS's COMP360 formulation, recognized as a Breakthrough Therapy by the FDA, has shown statistically significant improvements in depressive symptoms in clinical trials. The company continues to expand its innovative approach to mental health care.
COMPASS Pathways (CMPS) reported positive topline results from its phase IIb trial of COMP360 psilocybin therapy for treatment-resistant depression (TRD), indicating a rapid and sustained response from patients after a single 25mg dose. The company has also initiated a phase II study for PTSD and noted promising outcomes from an investigator-initiated study on cancer-related depression. Financially, COMPASS reported a net loss of $15.8 million for Q3 2021, with cash reserves of $294 million. The acquisition of an IP portfolio and new US patent for crystalline psilocybin were highlighted as advancements.
COMPASS Pathways plc (Nasdaq: CMPS) announced the successful results of its phase IIb clinical trial for COMP360 psilocybin therapy, targeting treatment-resistant depression (TRD). The trial involved 233 patients and achieved its primary endpoint, showing a statistically significant reduction in depressive symptoms with a 25mg dose compared to a 1mg dose, as indicated by a -6.6 points difference on the MADRS scale (p0.001). The therapy was well tolerated, with over of adverse events being mild or moderate. The company plans to initiate a pivotal phase III trial in 2022.
COMPASS Pathways (Nasdaq: CMPS) announced a Phase II clinical trial of COMP360 psilocybin therapy for PTSD on November 3, 2021. This multicenter study aims to evaluate the safety and tolerability of a single 25mg dose administered with psychological support, enrolling 20 adult participants. Conducted at King’s College London, the trial is part of COMPASS’s efforts to address the 40% of PTSD patients who do not respond to existing treatments. The primary endpoint is safety, with secondary endpoints assessing symptom improvement and quality of life.
COMPASS Pathways (CMPS) announced positive topline results from an open-label study of COMP360 psilocybin therapy for major depression in cancer patients. Conducted by Maryland Oncology Hematology, 50% of participants achieved remission in depression symptoms within one week, maintained for eight weeks. The study involved 30 patients, with an average initial MADRS score of 25.9, which dropped by 19.1 points after treatment. COMP360 therapy was well tolerated with no serious adverse events reported. Further research is anticipated to validate these promising results.